gadoxetic-acid-disodium and Uveal-Neoplasms

To determine the outcome of patients that underwent liver resection for metastases from uveal melanoma.. Over a 9-year period, patients referred with uveal melanoma metastases were included. Following treatment of primary uveal melanoma, high-risk patients were offered to be enrolled into a 6-monthly non-contrast liver magnetic resonance imaging (MRI) surveillance. Following detection of liver metastases, patients were staged with a contrast-enhanced (Primovist(®)) liver MRI, computer tomography (CT) of the thorax and staging laparoscopy.. 155 patients were referred with uveal melanoma liver metastases, of which 17 (11.0%) patients had liver resection and one patient was treated with percutaneous radio-frequency ablation. The majority of patients undergoing liver resection were treated with multiple metastectomies (n = 8) and three patients had major liver resections. The overall median survival for patients treated with surgery/ablation was 27 (14-90) months, and this was significantly better compared to patients treated palliatively [median = 8(1-30) months, P < 0.001]. Following surgery, 11 patients had recurrent disease [median = 13(6-36) months]. Patients who had undergone a major liver resection had a significantly poorer disease-free survival (P = 0.037).. Patients who can undergo surgical resection for metastatic uveal melanoma have a more favorable survival compared to those who do not.

Topics: Adult; Aged; Catheter Ablation; Contrast Media; Female; Gadolinium DTPA; Hepatectomy; Humans; Laparoscopy; Liver Neoplasms; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Palliative Care; Population Surveillance; Radiography, Thoracic; Tomography, X-Ray Computed; Uveal Neoplasms